Purpose: ALT-801 is a bifunctional fusion protein comprising interleukin-2 (IL-2) linked to a soluble, single-chain T-cell receptor domain that recognizes a peptide epitope (aa264-272) of the human p53 antigen displayed on cancer cells in the context of HLA-A Ã 0201 (p53þ/HLA-A Ã 0201). We evaluated the safety, pharmacokinetics, and pharmacodynamics of ALT-801 in p53þ/HLA-A Ã 0201 patients with metastatic malignancies. Experimental Design: p53þ/HLA-A Ã 0201 patients were treated with ALT-801 on a schedule of four daily 15-minute intravenous infusions, then 10 days rest and four more daily infusions. Cohorts of patients were treated at 0.015, 0.040, and 0.080 mg/kg/dose. Results: Four, 16, and 6 patients were treated at the 0.015, 0.04, and 0.08 mg/kg cohorts, respectively. Two dose-limiting toxicities (a grade 4 transient thrombocytopenia and a myocardial infarction) in the 0.08 mg/kg cohort established the maximum tolerated dose (MTD) at 0.04 mg/kg. Patients treated at the MTD experienced toxicities similar to those associated with high-dose IL-2 but of lesser severity. The serum half-life of ALT-801 was 4 hours and ALT-801 serum recovery was as expected based on the dose administered. ALT-801 treatment induced an increase of serum IFN-g but not TNF-a. Response assessment showed 10 subjects with stable disease at at least 11 weeks, and in one who had melanoma metastasis, there is an ongoing complete absence of identifiable disease after resection of radiographically identified lesions.
Introduction
Although treatment with high dose, bolus recombinant human interleukin-2 (IL-2; aldesleukin) can induce durable complete responses in a small fraction of patients with metastatic melanoma and kidney cancer, treatment is limited by significant toxicities, particularly hypotension, capillary leak syndrome, and oliguria (5) . One possible approach to improve the therapeutic ratio for IL-2-based treatment is more efficient targeting of lymphocytes with activated IL-2 receptor into the tumor microenvironment. To achieve this, ALT-801 has been developed as a tumortargeting immunotherapeutic (6) . Tumor cell recognition by ALT-801 is mediated by a T-cell receptor domain expressed in a recombinant single-chain format (scTCR) that has high affinity for a tumor associated antigen peptide spanning amino acids 264 to 272 of the p53 protein, presented on the cell surface by the HLA-A Ã 0201 complex (7) . In the ALT-801 protein, this scTCR has been engineered genetically to be linked to an IL-2 molecule. Intermediate and high-affinity IL-2 receptors on lymphocytes can be ligated by ALT-801, with subsequent immune activation comparable with that from unmodified IL-2. Theoretically, ALT-801-activated lymphocytes will have the same phenotype as IL-2-activated lymphocytes, but with the additional feature of a protein domain that recognizes a target on tumor cells.
The p53 protein has diverse physiologic function, including regulation of the cell cycle, and particularly G 2 /M arrest in the context of DNA damage. When p53 is mutated, as it is in many cancers, 2 key changes occur. Central to the malignant phenotype, the G 2 /M checkpoint function is impaired and cell cycling without adequate repair is accelerated. In addition, the stability of the normally labile protein increases, resulting in its accumulation in tumor cells and elevated presentation of p53-derived peptide antigens on the cell surfaces (8, 9) . The p53 (aa 264-272)/HLA-A Ã 0201 complex is significantly elevated in a wide range of human tumor tissues (10, 11) . The quantitatively differential display of p53 peptide antigens on tumor versus on normal cells defines an opportunity to use p53 positivity to direct TCR-based immunotherapeutics to target tumor cells. In several human xenograft murine models, we have shown that ALT-801 exhibits potent antitumor activity against p53þ/HLA-A Ã 0201 tumors but not p53À/HLA-A Ã 0201 tumors, regardless of the tissue of origin of the tumors (6, 7, 12) . Thus, ALT-801 has therapeutic potential as an immunotherapeutic targeting any tumor which is p53þ in an HLA-A Ã 0201 individual. In this first-in-man, phase I dose escalation study (ClinicalTrials.gov ID: NCT00496860), patients whose tumors bore p53 (aa 264-272)/HLA-A Ã 0201 complexes were treated with ALT-801. The goals of the study were to determine the safety, maximally tolerated dose and the anticancer activity of ALT-801 as monotherapy in humans. We assessed ALT-801 pharmacokinetic (PK) and pharmacodynamic effects on peripheral blood lymphocytes and serum cytokines.
Materials and Methods

Study population
The study protocol and consents were approved by the Institutional Review Boards of each clinical site. Eligible subjects were 18 years or older with progressive metastatic malignancy considered surgically and medically incurable who provided written informed consent. Serologic HLA-A2 testing [reactivity to anti-human HLA-A2 monoclonal antibodies (mAb), BB7.2 and MA2.1] was used to screen subjects and if positive, formalin-fixed paraffinembedded tumor specimens were tested at a central laboratory (Altor Bioscience Corp.) for immunohistochemically identifiable p53 (aa264-272)/HLA-A Ã 0201. This assessment was scored as 0, 1þ, 2þ, or 3þ, using p53 peptide-specific and control STAR multimer reagents as described previously (11) . Patients were eligible for enrollment if their tumor cells stained with a 1þ or greater score relative to nontumor cells.
Eligibility criteria included adequate cardiac function (pretreatment testing at treatment physician discretion); pulmonary reserve (for smokers, FEV1 ! 75% required); liver [aspartate aminotransferase and alkaline phosphatase 2.5 Â upper limit of normal (ULN); PT, aPTT 1.5 Â ULN]; kidney (creatinine 1.5 Â ULN); and marrow function (absolute neutrophil count ! 1,500/mL, platelets !100,000/mL, hemoglobin ! 10 g/dL); an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; life expectancy more than 12 weeks; and no concurrent corticosteroid use. Prior therapies must have been completed more than 4 weeks before enrollment (>6 weeks for nitrosoureas and >8 weeks for mAbs).
Treatment plan
Inpatient hospitalization and placement of a central venous catheter were required. Infusions were done at 4 U.S. clinical sites that had extensive experience in IL-2 (aldesleukin, Proleukin) high-dose bolus therapy. The treatment course was a cycle of 4 daily 15-minute intravenous infusions, with planned discharge home on the fifth day, then a 10-day interval off treatment, followed by a second similar cycle. This is illustrated in Table 1 . A second course of treatment was offered to patients with stable disease (SD), partial response (PR), or complete response (CR), at 7 weeks or later. Dose omission criteria are below.
The definition for dose-limiting toxicity (DLT) was based on the fact that toxicities of IL-2 are often significant, but rapidly reversible. The DLT events included those which would cause a discontinuation of the treatment during the first treatment course, specifically: grade 2þ cardiac
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On the basis of the PK profile in animals, the plasma concentrations of ALT-801 achieved at relatively low dose levels were expected to be sufficient to fully occupy intermediate-affinity (
10
À11 mol/L) IL-2 receptors on the surface of leukocytes (7, 13) . In addition, animal toxicity studies suggested the potential side effects of ALT-801 treatment would be qualitatively similar to that of IL-2 therapy. Thus, a dose level of 0.015 mg/kg/dose (equivalent to approximately 50,000 IL-2 IU/kg) was chosen as the first dosing level with a subsequent planned dose escalation up to 0.16 mg/kg/dose in a total of up to 5 cohorts (Table 2) . A conventional 3þ3 format dose escalation was used, with cohort escalation if none of 3 subjects had DLT events or expansion to 6 subjects if 1 of 3 subjects had DLT events. If 0 to 1 of 6 subjects had DLT events, the dose level would be considered tolerated. If 2 or more of initial 3 to 6 subjects had DLT events, the dose level would be considered to exceed the maximum tolerated dose (MTD). Ten additional patients were treated at the MTD.
Subject evaluations and correlative testing
Subjects had daily blood tests (complete blood count and comprehensive metabolic panel) during inpatient treatment, with additional testing as clinically indicated. Clinical response, determined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.0; ref. 14) , was assessed at 7 weeks (corresponding to 4 weeks after end of treatment), at 11 weeks as necessary to confirm a response at 7 weeks, or as otherwise clinically indicated.
Pharmacokinetics. Blood samples were collected at predosing on the first study and at approximately 15 and 30 minutes, and 1, 2, 4, 8, 12, and 24 hours postdosing on the first and fourth days in each of cycles. Serum concentrations of ALT-801 were determined using 2 different sandwich ELISAs, in which the sample was captured on anti-TCR Cb mAb (BF-1)-coated wells and detected with either biotinylated anti-IL-2 mAb (Pierce) or biotinylated anti-TCR Cb mAb (W4F), as described previously (7) . The first ELISA format measures intact ALT-801, whereas the second ELISA detects the TCR domain of ALT-801 only.
Immunogenicity. An ELISA method was used to screen for antibodies with specificity for ALT-801. A cell proliferation assay using IL-2-dependent CTLL-2 cells was used to test for neutralizing antibodies to the IL-2 domain of ALT-801 (12) .
Pharmacodynamics. Serum IFN-g and TNF-a levels were measured by ELISA methods according to the manufacturer's instructions (BD Bioscience-Pharmingen). To detect immune cell activation in patients during the ALT-801 treatment course, peripheral blood mononuclear cells (PBMC) were prepared from patient blood samples collected predosing (cycles 1 and 2) and 2 hours after the drug infusion of doses 3 and 7. 
Medication supply
ALT-801 (12) was provided by Altor BioScience Corporation in 2 mg/mL solution and reconstituted in D5W. The study drug was produced under cGMP conditions by recombinant CHO.K1 cells in serum-free culture medium and purified by immunoaffinity chromatography using the BF-1 mAb capture followed with ion-exchange chromatography and nanofiltration (12) . 
Clinical characteristics
Twenty-six patients received at least 1 dose of ALT-801, with an age range of 27 to 79 years. The most frequent diagnoses were melanoma and clear-cell kidney cancer. The dose levels are shown in Table 2 ; clinical characteristics of subjects are summarized in Table 3 . Three subjects were withdrawn from the study during treatment due to adverse events (AE). One subject died during the 28-day follow-up period, due to disease progression.
Adverse events
The range of observed AEs was similar across the 3 tested dose levels, with a high frequency of IL-2-associated side effects. As shown in Table 4 , the most frequent constitutional AEs observed in the dose escalation and MTD expansion phase of the study were fever (100% of subjects), chills/rigors (85%), and fatigue (42%). Common laboratory AEs were asymptomatic electrolyte imbalances (hypophosphatemia, hypocalcemia, and hyponatremia; 81% of subjects) and hypoalbuminemia (96% of subjects). Hematologic changes reported as AEs included thrombocytopenia (69% of Table 4 . Profile of AE, any attribution, of severity grade 3þ or occurring in more than 30% of patients Research.
on April 13, 2017. © 2011 American Association for Cancer clincancerres.aacrjournals.org Downloaded from subjects), anemia (65% of subjects), and lymphopenia (35% of subjects). Frequent cardiac-related AEs were hypotension (62% of subjects) and transient asymptomatic arrhythmias (42%).
Dose escalation experience
The first subject (age 79, metastatic renal cancer) on the first dose level (0.015 mg/kg/dose) had moderate hypotension, was treated with dopamine, and resolved within 24 hours. The protocol initially designated this as an AE causing discontinuation of treatment (which would be a DLT event); the protocol was revised. The patient was offered further treatment but declined and was replaced. No DLT events occurred in the next 3 subjects in cohort 1 and enrollment to the second cohort commenced.
In the 0.04 mg/kg/dose cohort, the third subject (age 30, refractory Hodgkin's lymphoma) experienced a grade 4 pleural effusion, designated as a DLT. The subject was intubated and required extensive supportive hospitalization, but she recovered and was discharged from hospital. There were no further DLT events in cohort 2 (0.04 mg/kg/ dose, 6 subjects) and the third cohort commenced.
In the 0.08 mg/kg/dose cohort, a subject (age 65, metastatic melanoma) had a DLT event of grade 4 thrombocytopenia that was asymptomatic. The event lasted 6 days and resolved without intervention. This event occurred after the full course of study drug infusion had been given. The treating investigator-designated attribution was not to the study drug; fluid administration and the disease site may have contributed. A second subject (age 64, nodular melanoma) had an acute myocardial infarction (grade 4 toxicity) as a DLT event after the sixth dose of ALT-801. This was considered probably related to the study drug; however, previously unsuspected highgrade atherosclerotic coronary obstruction was subsequently identified. Following angioplasty, the event resolved and the subject was discharged from the hospital and had no significant cardiac symptoms after discharge. A third serious AE in cohort 3 was grade 3 pneumonitis after the fifth dose, requiring prolonged hospitalization. The event subsequently resolved without additional treatment or intervention. A fourth event was an uncomplicated catheter-associated thrombosis, which was likely not drug or dose related, but was still considered directly related to the study procedures. The 2 DLTs of the 0.08 mg/kg cohort established the MTD at 0.04 mg/kg.
Three patients received a second course of treatment. For one of these patients (age 27, collecting duct/spindle cell cancer of kidney), abrupt visual loss occurred that was related to previously unappreciated bulky metastasis within the sinus causing impingement on the optic chiasm. This toxicity represented disease progression and was not attributed to ALT-801 treatment; however, ALT-801 treatment was discontinued.
In coordination with the pharmacodynamic testing (see below), the original treatment plan and discussion with the members of the Data Safety Monitoring Board, the 0.04 mg/ kg/dose level was designated as the MTD, completing the dose escalation phase of the study. Ten additional patients were treated at this dose level, as an expansion phase of the study. In the expansion cohort, the toxicities were qualitatively similar to those from the escalation phase, dominated by low-grade constitutional symptoms, gastrointestinal symptoms, and hypotension (Table 3) . Figure 2 shows the best response, by diagnosis and by cohort. Melanoma was the most frequent diagnosis and the one for which there was the most identifiable stabilization or regression. One subject (age 47, malignant melanoma) died within 28 days of last treatment (day þ26); the treating physician attributed the death to disease progression.
Tumor response
Of the 26 subjects enrolled, 3 (patients 1010, 4002, and 4003) had low level positive staining for p53 (aa 264-272)/ HLA-A Ã 0201 complex on their tumor specimens. None of these 3 subjects showed tumor response posttreatment, whereas SD was seen in 10 of 23 patients with tumor specimens staining at "2þ" or greater for p53 (aa 264-272)/HLA-A Ã 0201 complex. In the 0.04 mg/kg cohort, one subject with head and neck cancer had a target lesion of 30 mm in the nasopharyngeal sinus and had experienced progression of disease after 2 courses of cisplatin and docetaxel, prior to enrollment into the ALT-801 study. The patient had SD after the first course of ALT-801 treatment and then received the second course of ALT-801 treatment 5 months after the completion of the first. The SD continued to last for another 3.5 months with no other anticancer therapy.
Of the subjects receiving 0.08 mg/kg ALT-801, one who was diagnosed with stage IIIc melanoma originating from a primary lesion on his left lower leg, had subsequent development of multiple in-transit metastases as well as enlarged inguinal lymph nodes. Prior therapies included isolated limb perfusion but with subsequent progression clinically and by 2[18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). He was then enrolled on a clinical study of dacarbazine (DTIC) AE the experimental drug PI-88 (Progen Pharmaceuticals; NCT00130442). He was randomized to DTIC alone and received 15 cycles (11 months) of treatment. At that point, the disease status was SD. He elected to cross-over to PI-88 and received 10 days of treatment but developed an anti-heparin antibody response requiring termination from the study. Two months later, at the point of entry on the treatment reported in the present trial, sites of disease were multiple in-transit metastases of the left leg with an 8-mm target lesion and smaller lesions distally in the left groin. After one 8-dose course at the 0.08 mg/kg level, there was confirmed clinically and radiologically SD at week 11 (Fig. 2, patient 3001) . At 7 months after the first dose of ALT-801, restaging CT and FDG-PET scans and a series of biopsies (outside the planned treatment assessment of the present trial) were collected and showed no new lesions and no evidence of residual melanocytic tumor in the specimens examined. There were no pre-ALT-801 PET scans or biopsies for comparisons. The patient continues to exhibit no evidence of disease at 2þ years post-ALT-801 treatment, without any additional anticancer therapy.
Two other subjects in the 0.08 mg/kg/dose cohort also had SD; this was despite several missed doses during the course of ALT-801 treatment.
Altogether, 10 patients (38%) of 26 with various metastatic malignancies met SD criteria as best response. Available poststudy data for these SD patients with various diagnoses indicated a median progression-free survival of 7.3 months and a median overall survival of 21 months (Table 5 ). At least 8 of the 10 SD patients survived more than 1 year from the initiation of ALT-801 treatment.
Pharmacokinetics of ALT-801
Maximum concentration (C max ) of 405, 875, and 2335 ng/mL occurred 15 to 30 minutes after the start of the first dose of ALT-801 at the 0.015, 0.04, 0.08 mg/kg/dose groups, respectively. The C max observed in subsequent dosing was comparable with the values for the initial dosing (data not shown). Assuming an average plasma volume of approximately 40 mL/kg and uniform plasma distribution of the study drug, the calculated mean percent recovery of ALT-801 was 108%, 88%, and 117% for the 0.015, 0.04, and 0.08 mg/kg/dose levels, respectively. In addition, the ALT-801 molecule seemed intact throughout the study, based on the results of 2 ELISAs (data not shown).
Measurement of serum half-life on the initial dose showed comparable values across the dose range (4.4, 4.2, and 4.6 hours for the 0.015, 0.04, and 0.08 mg/kg/ dose cohorts, respectively). On subsequent doses of ALT-801, there was more variation, with the half-life range from 2.0 to 4.2 hours, depending on dose level and dose number. In subjects administered a second course of ALT-801 at 0.04 mg/kg, a C max of about 783 ng/mL and a serum half-life of 3.7 hours were observed after the first dose of the second course, comparable with the first-course treatment parameters.
In summary, the C max was proportional to dose and the serum initial half-life of ALT-801 was approximately 4 hours.
Immunogenicity
Immunogenicity testing by ELISA indicated that at 4 weeks after initial treatment, most treated patients developed anti-ALT-801 antibodies, as indicated by an increase in serum antibody titers compared with predose levels. For the 16 subjects receiving 0.04 mg/kg ALT-801, there was considerable variability in anti-ALT-801 antibody levels at week 4, with 1 subject showing no detectable titer and 2 subjects with titers greater than 20,000. Overall, the relative levels of anti-ALT-801 antibody decreased at the week 7 and 11 follow-ups (Fig. 3) . No IL-2-neutralizing antibodies were detectable in any sample, including samples with high anti-ALT-801 titers. In addition, none of the 3 subjects administered a second course of ALT-801 treatment experienced any allergic reaction following dosing.
Lymphocyte count and functional testing
An anticipated basic mechanistic feature triggered by ALT-801 treatment is the migration of IL-2 receptor-activated lymphocytes from the circulation into the peripheral tissues and p53-positive tumor (7) . This mechanism is consistent with the observed induced (total) lymphopenia, as evident in the daily blood cells analysis obtained during the treatment course (Fig. 4A) , which may be due to migration into the tumor, the periphery, or another location. Pharmacodynamic measurements included serum IFN-g and TNF-a levels and ELISPOT titer of IFN-g producing lymphocytes when tested with A375 human melanoma tumor cells [which bear the p53 (aa264-272)/HLA-A Ã 0201 complex]. Following ALT-801 administration, serum IFN-g levels increased and peaked 4 hours posttreatment before returning to baseline levels at 24 hours (Fig. 4B) . These changes were more pronounced in the later doses of the 4-day treatment cycles. In contrast, there was no change in serum TNF-a levels following ALT-801 administration. A detectable increase of numbers of lymphocytes with IFN-g production when exposed to ALT-801 and A375 cells was observed in PBMC specimens obtained just prior to the second course (Fig. 4C) . This was seen at about the same level in the 0.04 mg/kg/dose cohort as in the 0.08 mg/kg/ dose cohort, an observation that suggested that the higher dose was not definitely associated with a higher detectable immune response, so that continuation with the development of the 0.04 mg/kg/dose was supported by this portion of the correlative testing. Further studies are required to evaluate leukocyte types and antigen specificities responsible for these cell-mediated responses.
Discussion
The primary objective of the study was to define the toxicities and tolerability of and establish a safe dose for further clinical study of ALT-801. This study established the MTD of ALT-801 as 0.04 mg/kg/dose at a schedule of 8 doses over 2 cycles, given days 1 to 4 and 15 to 18. ALT-801 was tolerated at the MTD with acceptable toxicity. Common AEs were transient, readily managed with supportive care, within the expected range of experience with aldesleukin, and resolved after completion of ALT-801 treatment. Subjects administered ALT-801 at 0.04 mg/kg seemed to have a lower frequency of liver (elevated serum bilirubin) and kidney (oliguria, elevated serum creatinine) abnormalities and grade 3/4 hypotension events, than was reported in phase II studies of high-dose IL-2 therapy in treatment of metastatic melanoma or RCC (Table 4) . However, direct statistical comparison with other studies was not a trial objective and could be confounded by patient population differences.
A second course of ALT-801 treatment at the MTD was well tolerated in 3 patients. Anti-ALT-801 antibodies were detectable in the serum of patients 4 weeks after treatment and decreased over time posttreatment. No IL-2-neutralizing activity was observed, and any effects of anti-ALT-801 antibodies on ALT-801 pharmacokinetics, toxicity, and antitumor responses remain to be determined. Similar nonneutralizing immunogenicity has been observed in subjects following aldesleukin treatment (aldesleukin prescribing information: www.proleukin.com) and, thus, may be associated with this class of immunotherapeutic protein drugs.
The serum half-life of ALT-801 ranged between 2.0 to 4.6 hours depending on the dosing time and level. These results indicate that the half-life of this fusion protein is considerably longer than the reported 13 minutes distribution and 85 minutes elimination half-lives reported for aldesleukin (15) . Furthermore, the maximum serum ALT-801 concentrations observed were proportional with the ALT-801 dose, in contrast to the 30% serum recovery previously reported for subjects receiving aldesleukin therapy (prescribing information, www.proleukin.com). The C max at every dose displayed on the surface of lymphocytes (13) . Together with the observation of the ability of a single dose of ALT-801 to induce lymphocyte migration for several days and increase serum IFN-g levels 4 to 8 hours postdosing, these data support administration of ALT-801 as a once-daily or every-other day infusion rather than the every 8-hour infusion as used for high-dose IL-2 treatment.
A secondary objective of the study was to evaluate ALT-801 biological effects. An increase in mean serum IFN-g concentrations was seen 4 to 8 hours after dosing. In addition, subjects treated with 0.04 mg/kg or 0.08 mg/kg ALT-801 showed levels of serum IFN-g induction that were higher than those observed at the 0.015 mg/kg dose level. In contrast, little to no serum TNF-a was detected in any of the blood samples of the subjects, in contrast to subjects treated with IL-2 therapy in whom TNF-a is known to be induced after treatment (16) . The induction of TNF-a may be implicated in the etiology of IL-2 toxicity (17), but the relationship between ALT-801 treatment effects and TNF-a induction remains to be determined.
Another secondary objective was to assess the anticancer activity of ALT-801, although clearly the heterogeneity of the treated patients makes it hard to draw any conclusions. Of particular interest, many of the subjects had melanoma or clear-cell kidney cancer, and several patients with melanoma had SD with minor tumor shrinkage based on scans at 7 weeks and confirmed at 11 weeks. One patient who received the study drug at the 0.08 mg/kg dose had clinical and radiologic SD on ALT-801 treatment. Later, residual abnormalities were resected surgically and no disease was observed in the specimens, nor is there any detectable melanoma in the patient at 2þ years posttreatment. Whether the disease would have been in this complete remission for this duration if the patient had had just the pre-ALT-801 treatments and subsequent resections, as described above, or whether ALT-801 induced the pathologic response and the ongoing absence of any detectable disease is a question that is outside the scope of the available data. However, it is consistent to postulate that ALT-801 may have antitumor activity in patients with those diagnoses.
In addition, our observation in this study that ALT-801 induced SD in patients with progressive head and neck tumor, prostate cancer, and neuroendocrine cancer is consistent with studies in animal models in which ALT-801 exerted antitumor effects against p53-postive tumors regardless of their histology (12) . These findings suggest that the clinical utility of IL-2 immunotherapy could be broadened beyond melanoma and kidney cancer. Clinical trials are currently either underway or being planned to assess this possibility. The antitumor effects of ALT-801 also seem to be potentially durable, as evidenced by the long progression-free time or survival (12þ months) achieved in a number of the patients with advanced disease described here (see patients 1001, 2002, 1004, 1007, 2004, 3001, 4001 , and 4005 in Table 5 ). Durability of response is one of the hallmarks of successful immunotherapy, including high-dose IL-2 and anti-CTLA-4 antibodies (18, 19) .
There seemed to be a relationship between dose of ALT-801 and clinical response, as the highest dose level (0.08 mg/kg/dose) of ALT-801 was associated with better clinical benefit in some patients, including those who did not receive all 8 planned doses (Fig. 2) . However, the higher dose level was also associated with higher frequency and severity of AEs. Although the 4 days in-a-row schedule was developed working from the standard aldesleukin schedule and animal efficacy studies (7, 12) , other schedules can be considered. In animal studies, we have found recently that the toxicities associated with the current every-day-dosing regimen could be significantly lessened without sacrificing the efficacy of ALT-801 by employing an every-other-day dosing schedule (H.C. Wong, unpublished data). These findings suggest that dosing of ALT-801 at 0.08 mg/kg/dose or higher may still be feasible and pharmacodynamically adequate if ALT-801 doses are spaced more than 24 hours apart. Comparing the measurable pharmacodynamic impact of the 0.04 versus 0.08 mg/kg/doses in this study, the peak dose was approximately proportional, but either dose was sufficient to meet theoretical concentrations required for IL-2 receptor occupancy and subsequent lymphocyte activation (Fig. 4) . The relative real-world clinical relevance or sufficiency of these endpoints, however, is limited in comparison with the key issue of clinical responses. Thus, additional clinical studies and correlative testing will be key for defining a dose and schedule that are biologically optimal.
In a separate preclinical study, we have shown that the anticancer effect of ALT-801 could be significantly improved by increasing the density of the p53 (aa264-272)/HLA-A Ã 0201 complex on the tumor cell surface using chemotherapy, such as cisplatin, which may induce increased p53 levels ( H.C. Wong, unpublished data). Thus, further development of ALT-801 clinical application is anticipated in phase I clinical trials (ClinicalTrials.gov ID: NCT01029873 and NCT01326871) testing cisplatin followed by a lower frequency, every-other-day schedule of ALT-801. The relationship between HLA-A2/p53 peptide complex expression on tumors and biological response to ALT-801 will also be further evaluated. Although these preliminary results in this study support the trend that high level tumor expression of p53 (aa 264-272)/HLA-A Ã 0201 complex is important for ALT-801 antitumor responses, such an assessment was limited due to the small number of patients and the heterogeneity in tumor types examined. Thus, we believe that additional studies with more patients in a defined tumor type are needed before concluding on any relationship between p53 (aa 264-272)/HLA-A Ã 0201 tumor staining and patient responses. Although the ALT-801 þ cisplatin studies are currently limited to melanoma and urothelial cancer patients, the concept of chemotherapy-mediated p53 induction followed by targeted immunotherapy could be generalized to other cancers and to other p53-inducing treatments. In summary, this prospective solid tumor malignancy phase I dose escalation study provides first-in-human experience of ALT-801. At the MTD of 0.04 mg/kg/dose for a 4-days-in-a-row, multicycle dosing regimen, ALT-801 is adequately tolerated for practical use, with shown biological effect (IFN-g induction) and encouraging clinical activity. The proposed mechanism (i.e., overexpression of p53) spans multiple tumor types. We also observed changes in blood lymphocyte counts and in vitro immune reactivity of lymphocytes against target complex-bearing tumor cells in patients who received ALT-801. These data are consistent with the proposed mechanism of action of the fusion protein for IL-2-mediated immune cell activation followed by intratumoral accumulation of the activated immune cells via the p53 (aa264-272)/HLA-A Ã 0201-specific targeting domain of ALT-801 (7). Further clinical development of ALT-801 is warranted to establish its clinical utility and to coordinate administration with p53-inducing chemotherapy. 
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